Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats

Therapeutic Application of Allogeneic Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Regenerative Medicine

“…Two weeks after transplantation, the intravenous allogeneic transplantation of FM-MSCs reduced fibrosis, edema, necrosis, granulation and eosinophil infiltration in hearts exhibiting EAM and significantly attenuated infiltration of inflammatory cells (CD68-positive monocytes and macrophages) and MCP-1 expression in the myocardium ( Figure 4A and B). Hemodynamic and echocardiographic tests showed a significant improvement in cardiac function as a result of allogeneic FM-MSC transplantation (Ishikane et al, 2010). The extent of the improvement ranged from 30% to 60 according to various indices of the level of dysfunction, which is equivalent to that observed in our previous study on autologous BM-MSC transplantation in EAM (Ohnishi et al, 2007).…”

“…However, further experiments are needed to develop data obtained with MSCs for application to humans because evidence of an ameliorating effect on angiogenesis and cardiac function is not necessarily sufficient to warrant clinical use. To date, intramuscular and intravenous injections have been used for cell transplantation therapy, but the engraftment rate of MSCs transplanted via these routes was very low (Ishikane et al 2008(Ishikane et al , 2010. Although intramuscularly transplanted allogeneic FM-MSCs survived in ischemic hindlimb tissue for 3 weeks after transplantation, the number of engrafted cells decreased significantly.…”

“…In this review, we compare the cellular characteristics and utilization of FM-MSCs with those of BM-MSCs and discuss the potential of allogeneic FM-MSC transplantation therapy in the tissue regeneration (Ishikane et al 2008(Ishikane et al , 2010.…”

Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes

“…Further reports of MSC action in inflammatory in vivo settings indicated that MSC may reduce inflammation in obstructive sleep apnea [94], ischemia/reperfusion induced acute renal failure [95], liver fibrosis [96], experimental colitis [97], asthma [98], acute myocarditis [99], and myocardial infarction [100]. Moreover, one of the first reports of use of umbilical cord blood-derived mononuclear cells in diabetes pointed out that NOD mice treated with UCB mononuclear cells normalized blood glucose levels and increased their lifespan.…”

Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis

“…We have reported that intravenous injection of autologous bonemarrow (BM)-derived mesenchymal stem cells (BM-MSCs) and allogenic fetal membrane (FM)-derived MSC (FM-MSCs) ameliorates myocardial injury in rats with EAM [12,13]. Although we focused on the angiogenic effect and the paracrine action of transplanted MSCs on EAM in our previous study, we showed that allogenic FM-MSCs significantly reduced the proliferation and activity of T lymphocytes [12,13].…”